Truqap is actually a kinase inhibitor that works by blocking pathways that support the cancer cells survive and grow, so decreases cancer development. Truqap is from a class of medicines called an AKT inhibitor. Truqap received FDA acceptance on November seventeen, 2023, immediately after optimistic benefits with the CAPItello-291 Period https://davidy111lxh4.blog-kids.com/profile